Guerbet's innovation, Eluciremâ„¢ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with the highest relaxivity, in comparison to other availab ...
Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
The gadopiclenol extension for use in infants and neonates offers high-quality MRI contrast enhancement at half the standard gadolinium dose. The FDA has approved an extension of intravenous ...
DEAR MAYO CLINIC: I have had an acoustic neuroma for 10 years. When it was first diagnosed, I had fractionated stereotactic radiosurgery. Since then, I've had 18 MRIs with gadolinium injections. Have ...
June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
MERIDIAN, ID, UNITED STATES, February 11, 2026 /EINPresswire.com/ -- Raising Awareness, Educating Communities, and ...
In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results